NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.
| Autor: | Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Hendrie P, Lee AI, Lee JT, Mann J, McMahon B, Millenson MM, Morton C, Ortel TL, Ozair S, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Williams E, Zakarija A, Hammond L, Dwyer MA, Engh AM |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2018 Nov; Vol. 16 (11), pp. 1289-1303. |
| DOI: | 10.6004/jnccn.2018.0084 |
| Abstrakt: | Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of VTE in adult patients diagnosed with cancer or in whom cancer is clinically suspected. These NCCN Guidelines Insights explain recent changes in anticoagulants recommended for the treatment of cancer-associated VTE. (Copyright © 2018 by the National Comprehensive Cancer Network.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|